OBI Pharma, Inc. was informed by the patent office that patent for OBI-866 Immunogenic/Therapeutic Glycan Compositions And Uses Thereof has been granted by United States Patent and Trademark Office under the patent number 15/662,162. OBI-866 is an active immunotherapeutic cancer vaccine targeting SSEA-4, conjugating SSEA-4 and carrier protein KLH and triggers immune responses against hard-to-treat cancers once injected into the human system. OBI-866 has been granted by TFDA to proceed to Phase I human clinical study and is now open for enrollment actively.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
58.6 TWD | -0.68% | -3.62% | -15.56% |
1st Jan change | Capi. | |
---|---|---|
-15.56% | 417M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.02% | 40.47B | |
-10.87% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- 4174 Stock
- News OBI Pharma, Inc.
- United States Patent and Trademark Office Grants Patent for OBI-866 Immunogenic/Therapeutic Glycan Compositions and Uses Thereof